Alivus Life Sciences Limited Stock Price Today (NSE: ALIVUS)
Fundamental Score
Alivus Life Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alivus Life Sciences Limited share price today is ₹972.70, down 0.40% on NSE/BSE as of 30 March 2026. Alivus Life Sciences Limited (ALIVUS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹11.13K (Cr). The 52-week high for ALIVUS share price is ₹1225.10 and the 52-week low is ₹819.00. At a P/E ratio of 20.98x, ALIVUS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.69% and a debt-to-equity ratio of 0.02.
Alivus Life Sciences Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Alivus Life Sciences Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Alivus Life Sciences Share Price: A Conservative Valuation Analysis
The pharmaceutical industry, known for its defensive characteristics and inelastic demand, often presents opportunities for value investors. This analysis focuses on understanding the underlying financial health of Alivus Life Sciences Limited, specifically looking at the factors influencing the Alivus Life Sciences share price of ₹932.0. This price reflects a PE ratio of 20.98, a key metric we'll explore in relation to its profitability and capital allocation strategies.
One of the most promising aspects of Alivus Life Sciences is its impressive Return on Capital Employed (ROCE) of 24.92%. This figure indicates a strong ability to generate profits from its invested capital. In effect, this high ROCE acts as a protective moat around the business. A higher ROCE than the cost of capital implies efficient capital allocation and creates a barrier to entry for competitors. This superior profitability can lead to improved revenue growth and free cash flow, bolstering the intrinsic value of the company. The ability to reinvest capital at such a high rate is a crucial factor in long-term value creation.
Comparing Alivus Life Sciences to its peers offers valuable insights. For example, while
Mankind Pharma Ltd boasts a strong market position, a comparative analysis of management quality is crucial. Understanding the efficacy of management's capital allocation decisions and operational efficiency is critical. While a direct assessment of management quality requires a deeper dive, examining factors like revenue growth, operating margins, and strategic acquisitions (or lack thereof) can provide clues.Considering the current data available, including the PE ratio of 20.98 and the ROCE of 24.92%, Alivus Life Sciences presents an interesting profile for a value investor. Further investigation into debt levels, free cash flow generation, and competitive landscape is warranted to form a comprehensive valuation assessment. This analysis forms a small part of a comprehensive 80-parameter fundamental audit, independently verified by Sweta Mishra, focused on understanding the financial strength of the company. It remains crucial for investors to conduct thorough due diligence before making any investment decisions. We are merely offering observations, and not investment recommendations.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alivus Life Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALIVUS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (18.69%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.92%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (29.62%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 20.98 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (36.41%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (167.33x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1442.00 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Weak Earnings Growth (-52.37% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Alivus Life Sciences Limited Financial Statements
Comprehensive financial data for Alivus Life Sciences Limited including income statement, balance sheet and cash flow
About ALIVUS (Alivus Life Sciences Limited)
Alivus Life Sciences Limited is a global biopharmaceutical company dedicated to pioneering innovative solutions across a wide spectrum of therapeutic areas. With a robust research ...and development pipeline, Alivus focuses on the discovery, development, and commercialization of novel pharmaceutical products that address unmet medical needs. The company leverages cutting-edge technologies and a collaborative approach to accelerate the development of life-changing therapies for patients worldwide. Alivus Life Sciences is committed to maintaining the highest standards of quality and safety in all aspects of its operations, from research and development to manufacturing and distribution. Alivus Life Sciences Limited harnesses a diverse portfolio of advanced pharmaceutical ingredients, targeting prevalent and debilitating conditions. Specializing in creating intricate molecular compounds, Alivus caters to therapeutic areas such as oncology, neurology, and endocrinology. It offers an extensive range of pharmaceutical products, from innovative small molecules to complex biologics, designed to improve patient outcomes and enhance the quality of life. The company invests heavily in state-of-the-art manufacturing facilities, adhering to rigorous international regulatory standards, ensuring the consistent production of high-quality and safe pharmaceuticals. Alivus Life Sciences Limited operates with a global reach, providing healthcare solutions to diverse markets across continents. Its strategic partnerships and distribution networks enable the company to deliver its products to patients in need. By focusing on precision medicine and personalized therapies, Alivus is shaping the future of healthcare and empowering individuals to live healthier, more fulfilling lives. With a steadfast commitment to scientific excellence and patient-centricity, Alivus Life Sciences Limited is poised to remain a leader in the pharmaceutical industry for years to come.
Company Details
Key Leadership
Corporate Events
ALIVUS Share Price: Frequently Asked Questions
What is the current share price of Alivus Life Sciences Limited (ALIVUS)?
As of 30 Mar 2026, 12:07 pm IST, Alivus Life Sciences Limited share price is ₹972.70. The ALIVUS stock has a market capitalisation of ₹11.13K (Cr) on NSE/BSE.
Is ALIVUS share price Overvalued or Undervalued?
ALIVUS share price is currently trading at a P/E ratio of 20.98x, compared to the industry average of 31.77x. Based on this relative valuation, the Alivus Life Sciences Limited stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ALIVUS share price?
The 52-week high of ALIVUS share price is ₹1225.10 and the 52-week low is ₹819.00. These values are updated daily from NSE/BSE price data.
What factors affect the Alivus Life Sciences Limited share price?
Key factors influencing ALIVUS share price include quarterly earnings growth (Sales Growth: 16.00%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alivus Life Sciences Limited a good stock for long-term investment?
Alivus Life Sciences Limited shows a 5-year Profit Growth of 8.92% and an ROE of 18.69%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in ALIVUS shares.
How does Alivus Life Sciences Limited compare with its industry peers?
Alivus Life Sciences Limited competes with major peers in the Pharmaceuticals. Investors should compare ALIVUS share price P/E of 20.98x and ROE of 18.69% against the industry averages to determine competitive standing.
What is the P/E ratio of ALIVUS and what does it mean?
ALIVUS share price has a P/E ratio of 20.98x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is ALIVUS performing according to Bull Run's analysis?
ALIVUS has a Bull Run fundamental score of 68.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ALIVUS belong to?
ALIVUS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alivus Life Sciences Limited share price.
What is Return on Equity (ROE) and why is it important for ALIVUS?
ALIVUS has an ROE of 18.69%, which indicates excellent management efficiency. ROE measures how efficiently Alivus Life Sciences Limited generates profits from shareholders capital.
How is ALIVUS debt-to-equity ratio and what does it indicate?
ALIVUS has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is ALIVUS dividend yield and is it a good dividend stock?
ALIVUS offers a dividend yield of 0.55%, meaning you receive ₹0.55 annual dividend for every ₹100 invested in Alivus Life Sciences Limited shares.
How has ALIVUS share price grown over the past 5 years?
ALIVUS has achieved 5-year growth rates of: Sales Growth 9.20%, Profit Growth 8.92%, and EPS Growth -52.37%.
What is the promoter holding in ALIVUS and why does it matter?
Promoters hold 74.91% of ALIVUS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Alivus Life Sciences Limited.
What is ALIVUS market capitalisation category?
ALIVUS has a market capitalisation of ₹11126 crores, placing it in the Mid-cap category.
How volatile is ALIVUS stock?
ALIVUS has a beta of N/A. A beta > 1 suggests the Alivus Life Sciences Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ALIVUS operating profit margin trend?
ALIVUS has a 5-year average Operating Profit Margin (OPM) of 29.62%, indicating the company's operational efficiency.
How is ALIVUS quarterly performance?
Recent quarterly performance shows Alivus Life Sciences Limited YoY Sales Growth of 16.00% and YoY Profit Growth of 36.41%.
What is the institutional holding pattern in ALIVUS?
ALIVUS has FII holding of 6.84% and DII holding of 5.47%. Significant institutional holding often suggests professional confidence in the Alivus Life Sciences Limited stock.